QDEL - Quidel Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
64.41
+0.24 (+0.37%)
As of 1:15PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close64.17
Open64.40
Bid64.19 x 900
Ask64.39 x 1800
Day's Range63.75 - 64.80
52 Week Range33.01 - 77.63
Volume94,319
Avg. Volume261,723
Market Cap2.515B
Beta1.47
PE Ratio (TTM)112.41
EPS (TTM)0.57
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.80
Trade prices are not sourced from all markets
  • Is Quidel Corporation’s (NASDAQ:QDEL) Liquidity Good Enough?
    Simply Wall St.yesterday

    Is Quidel Corporation’s (NASDAQ:QDEL) Liquidity Good Enough?

    Stocks with market capitalization between $2B and $10B, such as Quidel Corporation (NASDAQ:QDEL) with a size of US$2.53b, do not attract as much attention from the investing community as doRead More...

  • Are Options Traders Betting on a Big Move in Quidel (QDEL) Stock?
    Zacksyesterday

    Are Options Traders Betting on a Big Move in Quidel (QDEL) Stock?

    Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.

  • 3 Top Stocks From the Booming US Medical Products Industry
    Zacks5 days ago

    3 Top Stocks From the Booming US Medical Products Industry

    The U.S. Medical Products industry is sturdy on solid focus on technological advancement.

  • Medical - Products Stock Outlook: Short-Term Pain Inevitable
    Zacks7 days ago

    Medical - Products Stock Outlook: Short-Term Pain Inevitable

    Medical - Products Stock Outlook: Short-Term Pain Inevitable

  • Zacks20 days ago

    Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position

    Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.

  • Benzinga25 days ago

    The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Avid Bioservices Inc (NASDAQ: ...

  • Business Wire26 days ago

    Quidel Receives FDA Clearance, CLIA Waiver for Its Point-of-Care Sofia® 2 Lyme Fluorescent Immunoassay for Use with Sofia® 2 Instrument from Finger-Stick Whole Blood Specimens

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the United States Food and Drug Administration (FDA) to market its Sofia 2 Lyme FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from finger-stick whole blood specimens from patients suspected of B. burgdorferi infection. The test is intended for use with the Sofia 2 analyzer to aid in the diagnosis of Lyme disease.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of QDEL earnings conference call or presentation 7-Aug-18 9:00pm GMT

    Q2 2018 Quidel Corp Earnings Call

  • Implied Volatility Surging for Quidel (QDEL) Stock Options
    Zackslast month

    Implied Volatility Surging for Quidel (QDEL) Stock Options

    Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.

  • Quidel (QDEL) Surpasses Q2 Earnings and Revenue Estimates
    Zacks2 months ago

    Quidel (QDEL) Surpasses Q2 Earnings and Revenue Estimates

    Quidel (QDEL) delivered earnings and revenue surprises of 63.64% and 0.98%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Quidel: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 8 cents. Earnings, adjusted for one-time gains and costs, came to 36 cents per share. The results beat Wall Street expectations. ...

  • Business Wire2 months ago

    Quidel Reports Second Quarter 2018 Financial Results

    Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2018.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Federated Investors, SailPoint Technologies, Quidel, L3 Technologies, Pentair plc, and Veeva — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Federated ...

  • Business Wire2 months ago

    Quidel to Hold Second Quarter 2018 Financial Results Conference Call on August 7, 2018

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second quarter 2018 financial results after market close on Tuesday, August 7, 2018. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions.

  • Business Wire2 months ago

    Quidel Receives FDA Clearance for Solana® Bordetella Complete® Molecular Diagnostic Assay for the Detection of Pertussis (Whooping Cough), Parapertussis Infections

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Solana Bordetella Complete Assay, a molecular diagnostic assay to be used with the Solana molecular diagnostic instrument for the qualitative detection and differentiation of Bordetella pertussis and Bordetella parapertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to Bordetella pertussis and Bordetella parapertussis. Pertussis, or whooping cough, is a very contagious disease caused by the Bordetella pertussis bacteria, which attach to the cilia that line part of the upper respiratory tract, causing inflammation through the release of toxins, which cause airways to swell.1 Pertussis is spread from person to person through the inhalation of bacteria from an infected person’s cough or sneeze.

  • Is Quidel Corporation (NASDAQ:QDEL) Worth US$069.58 Based On Intrinsic Value?
    Simply Wall St.3 months ago

    Is Quidel Corporation (NASDAQ:QDEL) Worth US$069.58 Based On Intrinsic Value?

    I am going to run you through how I calculated the intrinsic value of Quidel Corporation (NASDAQ:QDEL) by projecting its future cash flows and then discounting them to today’s value.Read More...

  • Implied Volatility Surging for Quidel (QDEL) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for Quidel (QDEL) Stock Options

    Investors need to pay close attention to Quidel (QDEL) stock based on the movements in the options market lately.

  • Business Wire4 months ago

    Quidel to Present at William Blair 38th Annual Growth Stock Conference

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 38th Annual Growth Stock Conference at the Four Seasons hotel in Chicago, Illinois on Tuesday, June 12, 2018. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on Tuesday, June 12, 2018 at 2:10 p.m. Central Time (12:10 p.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends.

  • Business Wire4 months ago

    Quidel Announces Private Exchange Transactions

    Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $32.678 million in aggregate principal amount of the 2020 Notes for (i) approximately 927,470 shares of the Company’s common stock plus (ii) an additional number of newly issued shares of the Company’s common stock to be determined based on the volume weighted average price of the Company’s common stock over the three consecutive trading days commencing on June 1, 2018.

  • Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
    Zacks4 months ago

    Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?

    Smart Beta ETF report for XHE

  • Business Wire4 months ago

    Quidel to Present at UBS Global Healthcare Conference

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the UBS Global Healthcare Conference at the Grand Hyatt New York hotel in New York, New York on Wednesday, May 23, 2018. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on Wednesday, May 23, 2018 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. During the presentation, the company will discuss business and financial developments and trends.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of QDEL earnings conference call or presentation 8-May-18 9:00pm GMT

    Q1 2018 Quidel Corp Earnings Call

  • Associated Press5 months ago

    Quidel: 1Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had net income of 86 cents. Earnings, adjusted for one-time gains and costs, were $1.29 per share. The results topped Wall Street expectations. ...

  • Business Wire5 months ago

    Quidel Reports First Quarter 2018 Financial Results

    Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2018.

  • Business Wire5 months ago

    Quidel to Hold First Quarter 2018 Financial Results Conference Call on May 8, 2018

    Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2018 financial results after market close on Tuesday, May 8, 2018. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions.